This phase 1 clinical trial evaluated danuglipron, a small-molecule oral GLP-1 receptor agonist, for safety, pharmacokinetics, and preliminary efficacy in adults with type 2 diabetes. Danuglipron produced dose-dependent improvements in fasting plasma glucose, postprandial glucose, and body weight. Preclinical validation was supported by studies using a humanized GLP1R mouse model developed by genOway.
Danuglipron demonstrated promising glycemic control and weight reduction effects, validating the approach of targeting human GLP-1R with an oral small-molecule agonist.
Humanized GLP1R Knockin mouse model developed by genOway, with the human GLP1R extracellular domain replacing the mouse counterpart for preclinical drug evaluation.
Type 2 diabetes, Oral GLP-1 therapy, Small-molecule GLP-1R agonist, Glycemic control
Humanized Knockin model, GLP1R extracellular domain replacement, Preclinical pharmacology
From model design to experimental results
Tailor-made solutions adapted to scientific questions
Comprehensive dataset package
Generated with biopharma partners and in-house
Scientific follow-up and advice along the project
Collaborative approach for problem solving and development of innovative models
Breeding facilities in US and Europe
Certified health status from professional breeders
